Hematology & Blood Cancer
Advertisement
It is now “first and only” bispecific T-cell engager therapy approved for consolidation treatment regardless of MRD ...
Lorna Warwick discusses how nurses can connect patients with resources from the coalition and its member organizations.
An exploratory analysis of the MOMENTUM trial evaluated how the JAK inhibitor impacted OS and LFS in these patients.
Lorna Warwick, CEO of Lymphoma Coalition, discusses how nurses can strengthen bonds with patients through communication.
Erik Aerts, RN, and Mairéad Ní Chonghaile, RGN, BNS, MSc, discuss the congress and the resources HNHCP offers for nurses.
Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks about the importance of staying current on the latest updates in the field.
Erik Aerts, RN, shares why it was critical for nurses to attend the EHA 2024 Congress in Madrid, Spain.
National Cancer Survivors Month is marked in June each year.
Lorna Warwick discusses the important role that nurses serve in ensuring patients receive care and information.
Valeria Santini, MD, shares her insights during the European Hematology Association 2024 Congress.
An MPN program director discusses the key elements that oncology nurses should keep in mind when observing these patients.
Ms. Warwick discusses what nurses should know about results from the coalition's global patient survey.
A real-world study presented at the EHA 2024 Congress provided insights on patient and caregiver experiences.
Nursing managers should be aware of how standard infection prevention behaviors among nurses may vary.
A continuing education program helped nurses function collaboratively as part of a multidisciplinary team.
Sexual side effects are common in patients undergoing stem cell transplant but, unfortunately, often go unaddressed.
The study showed that nursing support was a “key environmental facilitator" for physical activity in these patients.
Andrea Wagner, MSN, RN, OCN, speaks about her ONS Congress presentation on the development of the workflow.
Researchers analyzed data from more than 1 million people to determine blood cancer mortality rates from 2000-2020.
There is a “lack of consistency” among patient-reported outcome measures used to evaluate CML treatments.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.